Results 41 to 50 of about 5,337 (191)

Is Aducanumab a Miracle Drug?

Journal of Student Research, 2022
A new drug called Aducanumab has been circulating the medical news for a while along with many questions. To answer these questions, it is imperative to understand Alzheimer’s disease.  This research was done by reading other articles and observing scans to truly comprehend the premise of the problems.
Sanjana Ananthula, Rajagopal Appavu, Josthana Kethar   +2 more
openaire   +1 more source

Development of monoclonal antibody therapeutics for alzheimer's disease

Taiwanese Journal of Psychiatry, 2022
Background: In a previous review article in the Taiwanese Journal of Psychiatry (Takeda and Tagami: Taiwanese J. Psychiatry 2020; 34: 152-61), we gave the development status of drugs for Alzheimer's disease, presented a relatively pessimistic view, and ...
Masatoshi Takeda
doaj   +1 more source

El caso de aducanumab ¿Más esperanza que ciencia?

ARS Medica, 2021
En junio, la Agencia de Alimentos y medicamentos de los Estados Unidos (FDA) otorgó aprobación mediante vía acelerada al medicamento aducanumab, desarrollado por Biogen, Inc.  para tratamiento de la enfermedad de Alzheimer (EA).  Esta autorización no ha
Eliana Sánchez-Montoya, Max Andresen, Raúl Corrales, Jorge Gallardo, Viviana Noriega, Caroline R. Weinstein-Oppenheimer   +5 more
doaj   +1 more source

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab

Canadian Geriatrics Journal, 2021
Alzheimer’s disease is a major cause of morbidity and mortality. Currently, there are no disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid-beta in the
Howard Chertkow, Kenneth Rockwood, David B. Hogan, Natalie Phillips, Manuel Montero-Odasso, Shabbir Amanullah, Sandra Black, Christian Bocti, Michael Borrie, Howard Feldman, Morris Freedman, Robin Hsiung, Andrew Kirk, Mario Masellis, Haakon Nygaard, Tarek Rajji, Louis Verret   +16 more
doaj   +1 more source

A narrative review on preclinical/clinical trials on aducanumab [PDF]

Scripta Medica
The most widespread type of dementia, Alzheimer's disease (AD), is predicted to triple in global prevalence by 2050. AD has a substantial societal and economic impact across the world, negatively affecting both patients and their caregivers, as the ...
Goel Akriti, Garima, Jain Paras, Bansal Seema, Chopra Hitesh, Gupta Sumeet, Kumar Satish, Dhanawat Meenakshi, Aggarwal Navidha   +8 more
doaj   +1 more source

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab [PDF]

, 2023
Objectives: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s disease (AD) have been published.
Vellas, B, Tian, Y, van Dyck, CH, Rajagovindan, R, Cohen, S, Mummery, CJ, Muralidharan, KK, Dent, G, Hansson, O, Chen, T, Barkhof, F, Iwatsubo, T, Aisen, PS, Nestorov, I, Sandrock, A, Budd Haeberlein, S, Harrison, K, von Hehn, C, Nisenbaum, L, Mallinckrodt, C, Zhu, Y, Wu, S   +21 more
core   +2 more sources

Aducanumab therapy to treat Alzheimer\u27s disease: A narrative review

, 2022
Background. Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer\u27s disease (AD).
Beshir, Semira Abdi, Menon, Vineetha Bharathan, Parveen, Affana, Hussain, Nadia, Goh, Sheron Sir Loon, Aadithsoorya, A.M.   +5 more
core   +1 more source

Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system

Frontiers in Pharmacology
ObjectiveStudies on anti-Aβ drugs for the treatment of Alzheimer’s disease (AD) have garnered significant attention; however, their safety still requires further research and monitoring. Although recent studies have analyzed the adverse drug events (ADEs)
Lingti Kong, Lingti Kong, Lingti Kong, Xiaohu Yang, Xiaohu Yang, Jian Xu, Jian Xu   +6 more
doaj   +1 more source

Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy.

Frontiers in Neurology, 2015
Amyloid Related Imaging Abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD).
Jacopo C. DiFrancesco, Jacopo C. DiFrancesco, Martina eLongoni, Martina eLongoni, Fabrizio ePiazza, Fabrizio ePiazza, Fabrizio ePiazza   +6 more
doaj   +1 more source

Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease

Pharmaceutics, 2021
Physiological and pathological ageing (as exemplified by Alzheimer’s disease, AD) are characterized by a progressive decline that also includes cognition. How this decline can be slowed or even reversed is a critical question.
Jürgen Götz, Gina Richter-Stretton, Esteban Cruz   +2 more
doaj   +1 more source